This HTML5 document contains 75 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
n10http://dx.doi.org/10.1159/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n12http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q37595259
rdf:type
wikibase:Item
schema:description
vedecký článok wissenschaftlicher Artikel научни чланак artículu científicu espublizáu en 2009 vědecký článek artigo científico наукова стаття, опублікована в липні 2009 article científic wetenschappelijk artikel articolo scientifico مقالة علمية نشرت في 20 يوليو 2009 vetenskaplig artikel bilimsel makale videnskabelig artikel article scientifique bài báo khoa học scientific article published on 20 July 2009
p:P577
wds:Q37595259-B49CACC9-4B05-4E51-AFD3-7EC0EB574559
wdt:P577
2009-07-20T00:00:00Z
p:P2093
wds:Q37595259-FE891AA8-EF5B-4E8F-BBB7-2DFAB8912C5E wds:Q37595259-A9344581-25B8-4A59-BA59-1DC587D50830 wds:Q37595259-7286BDD2-B9BF-4DEA-9A7B-8EB85B09D1C0 wds:Q37595259-2FEC4011-AE1E-4975-AFFD-0C7A5BDC3BEB wds:Q37595259-420F2CC4-FFDE-4524-A472-05C1310D8104 wds:Q37595259-944B1FAE-9636-46E5-8389-5E53A60E91E9 wds:Q37595259-25437870-73D8-4F32-A8C5-BAA4A1C21FAD
wdt:P2093
Ludovic Astier Laura Biganzoli Thomas Nagykalnai Stephane Munier Vera Gorbunova Svetislav Jelic Juris Berzins
rdfs:label
Doxorubicin and paclitaxel versus fluorouracil, doxorubicin and cyclophosphamide as first-line therapy for women with advanced breast cancer: long-term analysis of the previously published trial Doxorubicin and paclitaxel versus fluorouracil, doxorubicin and cyclophosphamide as first-line therapy for women with advanced breast cancer: long-term analysis of the previously published trial Doxorubicin and paclitaxel versus fluorouracil, doxorubicin and cyclophosphamide as first-line therapy for women with advanced breast cancer: long-term analysis of the previously published trial
skos:prefLabel
Doxorubicin and paclitaxel versus fluorouracil, doxorubicin and cyclophosphamide as first-line therapy for women with advanced breast cancer: long-term analysis of the previously published trial Doxorubicin and paclitaxel versus fluorouracil, doxorubicin and cyclophosphamide as first-line therapy for women with advanced breast cancer: long-term analysis of the previously published trial Doxorubicin and paclitaxel versus fluorouracil, doxorubicin and cyclophosphamide as first-line therapy for women with advanced breast cancer: long-term analysis of the previously published trial
schema:name
Doxorubicin and paclitaxel versus fluorouracil, doxorubicin and cyclophosphamide as first-line therapy for women with advanced breast cancer: long-term analysis of the previously published trial Doxorubicin and paclitaxel versus fluorouracil, doxorubicin and cyclophosphamide as first-line therapy for women with advanced breast cancer: long-term analysis of the previously published trial Doxorubicin and paclitaxel versus fluorouracil, doxorubicin and cyclophosphamide as first-line therapy for women with advanced breast cancer: long-term analysis of the previously published trial
p:P50
wds:Q37595259-5B875B5F-9FC6-4F2E-A3DE-67C8950F2F27 wds:Q37595259-A2A08279-A5D7-48C6-93D0-939A6FCB0D7C wds:Q37595259-A5B2438C-F034-4E54-997E-B3A1240DD19D wds:Q37595259-091FB70E-0B82-42B0-A9B4-34B721662A93
wdt:P50
wd:Q125317273 wd:Q38290512 wd:Q19690551 wd:Q125317615
p:P1476
wds:Q37595259-D5390599-F561-414C-8686-B958361B6151
wdt:P1476
Doxorubicin and paclitaxel versus fluorouracil, doxorubicin and cyclophosphamide as first-line therapy for women with advanced breast cancer: long-term analysis of the previously published trial
p:P304
wds:Q37595259-F935B290-1B47-4E68-90DA-B34556224336
wdt:P304
468-472
p:P31
wds:Q37595259-7F9DA443-45C1-4EA5-8F30-A9266364FD01
wdt:P31
wd:Q13442814
p:P921
wds:Q37595259-1674C156-0148-46CE-853F-36004428920D wds:Q37595259-23ED185E-02C6-4134-A469-54DDE114C9C5 wds:Q37595259-D2723904-DD90-4786-9B9A-171527C0EF62
wdt:P921
wd:Q423762 wd:Q18936 wd:Q238512
p:P698
wds:Q37595259-BC22621B-5503-452A-BB53-2C2EC2875E6B
wdtn:P698
n12:19745590
wdt:P698
19745590
p:P1433
wds:Q37595259-BB87767B-A210-4A0C-B9E7-88E2F0D6E1FF
wdt:P1433
wd:Q15759087
p:P433
wds:Q37595259-BEF66C43-18BA-465C-98DA-F4229B0FDC15
p:P478
wds:Q37595259-110C8813-10C8-4FE4-9A94-6A0FBCCC045C
wdt:P433
8-9
wdt:P478
32
p:P356
wds:Q37595259-FF297709-0DEB-4A19-8EE0-8E939BD64D42
wdtn:P356
n10:000226210
wdt:P356
10.1159/000226210